Head-to-head · WeighScore
Curve vs Ivim Health
The verdict
Curve takes it — 61.9/100 to 59.6/100.
Curve grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Curve (Try Curve LLC) is a telehealth platform offering compounded semaglutide and tirzepatide, prescribed by Beluga Health providers licensed in all 50 states and dispensed by VialsRx, a US 503A…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Curve | Ivim Health |
|---|---|---|
| WeighScore | 61.9/100 | 59.6/100 |
| Grade | C | C |
| Scorecard rank | #280 | #338 |
| Semaglutide | $175/mo (compounded) | $149/mo (starting dose, medication and programme fee, compounded) |
| Tirzepatide | $225/mo (compounded) | $224/mo (starting dose, medication and programme fee, compounded) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #280 · C
Strengths
- Offers both compounded semaglutide and tirzepatide, with every dose priced the same so cost does not rise as you titrate up.
- LegitScript-certified (seal #51079066) and names both its 503A compounding pharmacy, VialsRx, and its provider network, Beluga Health.
- Transparent tiered pricing with a real month-to-month option; consultation, medication, and free expedited shipping included, no membership.
- Available in all 50 states with same-day provider review; no insurance needed and HSA/FSA accepted.
Where it loses points
- Very new (2026 launch) with a thin track record; the site still shows a Webflow template credit and a leftover Cora reference in its Terms.
- The cheapest headline rates ($99 semaglutide / $135 tirzepatide) require a 12-month prepay; true month-to-month is $175 and $225.
- Both product pages currently display an out-of-stock status, so availability may be inconsistent.
- Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.
Graded #338 · C
Strengths
- Both molecules are priced on one page, each quoted as medication and programme charge included rather than as a bare drug price
- A six-month commitment brings tirzepatide down to $133/mo, and the term is published rather than hidden
- The first month of the membership is free
Where it loses points
- A $75/mo membership is marketed as a separate product, and whether it is charged on top of the $149 medication rate is not stated anywhere we could find
- The $133/mo tirzepatide rate advertised on the homepage requires a six-month commitment; the month-to-month rate is $224
- Both figures are 'starting at' rates, so the cost of a titrated dose is not published
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.